ArticleGynecologic oncology reports2026
Pembrolizumab-associated hemophagocytic lymphohistiocytosis in recurrent metastatic squamous cell carcinoma of the ovary arising in a teratoma.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The expanding use of immune checkpoint inhibitors (ICIs) in gynecologic oncology has been accompanied by an increasing incidence of immune related adverse events (irAEs), requiring rapid recognition and management to prevent significant morbidity and mortality (Conroy and Naidoo, 2022, Liu et al., 2023, Kanji et al., 2022). Hematologic immune related adverse events remain particularly challenging due to their rarity, nonspecific presentation, and diagnostic complexity (Kroll et al., 2022). Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome that is life-threatening if not promptly identified and treated (Henter, 2025). Case report: We report a case of pembrolizumab associated HLH in a patient with recurrent metastatic squamous cell carcinoma of the ovary arising in a teratoma. The patient presented with persistent fevers, cytopenias, and laboratory abnormalities concerning for immune mediated toxicity following pembrolizumab therapy. Diagnostic evaluation highlighted the challenges of distinguishing HLH from other causes of systemic inflammation and infection in the oncology setting. Both HLH 2024 criteria and the HScore were utilized to support the diagnosis (Naymagon et al., 2025). The patient was successfully treated with steroid monotherapy with clinical and laboratory improvement. Conclusion: HLH remains a rare but potentially fatal immune related adverse event associated with immune checkpoint inhibitors. We review previously reported cases of HLH in gynecologic malignancies, including two cases in cervical cancer, two in ovarian cancer, and one in endometrial cancer (Wei et al., 2024, Rollet et al., 2024, Nosratian-Baskovic et al., 2016, Li et al., 2022). Increased awareness, early diagnostic consideration, and prompt treatment are essential to improve outcomes in patients receiving immune checkpoint inhibitors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.